Vivus (VVUS) said today it has resubmitted its new drug application for obesity treatment Qnexa to the U.S. food and Drug Administration.
The resubmission follows an agreement reached with an FDA committee seeking approval with a contraindication for women of childbearing potential.
The company has been in a race to develop an FDA-approved obesity drug, vs. rivals Arena Pharmaceuticals (ARNA) and Orexigen (OREX).
Also today, Anadys Pharmaceuticals (ANDS) said it has agreed to be acquired by Roche for $3.70 per share in cash, a 256% premium over the stock's closing price on Friday.
Roche said the acquisition augments its already strong hepatitis C portfolio.
And, keep an eye on Par Pharmaceutical (PRX) shares today.
The company has filed a complaint and motion for a preliminary injunction that would preserve its free speech right to 'provide truthful information to physicians and other healthcare providers' about the use of Megace, its weight-loss treatment drug for AIDS patients.
Doctors frequently prescribe the drug to treat wasting in cancer and geriatric patients, Par said, and FDA rules purport to ban the company from discussing such off-label uses for the drug.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.